Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and gut microbiota pattern in type 2 diabetes mellitus
RBR-5xhygvdCompleted
- Sponsor
- Universidade Estadual de Campinas
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM) and prediabetes, sponsored by Universidade Estadual de Campinas. Primary endpoint: Gut bacterial pattern. Started Jun 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on RBR-5xhygvd.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-5xhygvd.